Try our Advanced Search for more refined results

Skiadas v. Acer Therapeutics Inc. et al

Track this case

Case Number:

1:19-cv-06137

Court:

New York Southern

Nature of Suit:

Securities/Commodities

Multi Party Litigation:

Class Action

Judge:

Gregory H. Woods

Firms

Companies

Sectors & Industries:

  1. July 22, 2021

    Drugmaker Acer To Pay $8.35M To End Investor Suit

    Drugmaker Acer Therapeutics Inc. has agreed to pay $8.35 million to end investor claims that it misrepresented conversations it had with the U.S. Food and Drug Administration, which allegedly hurt investors when its share prices fell after the FDA rejected a new drug application the company had submitted.

  2. July 22, 2020

    Biotech Co. Must Face Securities Suit Over FDA Rejection

    A New York federal judge on Tuesday rejected a bid from Acer Therapeutics to reverse his decision to allow a proposed securities class action to continue as it alleges the biotech company misrepresented conversations with the U.S. Food and Drug Administration and hurt investors after the FDA rejected a new drug application.

  3. June 17, 2020

    Biotech Co. Investors' FDA Convo Suit Survives Dismissal Bid

    A Manhattan federal judge on Tuesday pared down a proposed class action alleging biotech company Acer Therapeutics and two of its executives misrepresented its conversations with the U.S. Food and Drug Administration, which allegedly hurt Acer investors after the regulator rejected a new drug application the company filed.

  4. February 10, 2020

    Acer Therapeutics Tries To Shake Suit Over FDA Rejection

    Acer Therapeutics is pushing a New York federal court to dump a proposed shareholder class action accusing the small pharmaceutical company of misrepresenting expectations for a new drug to get U.S. Food and Drug Administration approval, arguing that the money and effort it poured into the drug's development proves otherwise.